Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference
GT Biopharma announced that Dr. Jeffrey S. Miller will update on the GTB-3550 TriKE™ Phase I trial at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GT Biopharma announced that Dr. Jeffrey S. Miller will update on the GTB-3550 TriKE™ Phase I trial at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. This session will accompany the Company's corporate update presentation. A live webcast will be available on GT Biopharma's website, with a replay archived for 30 days post-event. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE™ NK cell engager technology, developed in partnership with the University of Minnesota.
Details
News Market Reaction – GTBP
The recorded move for GTBP in the trading session of this news was -7.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEVERLY HILLS, Calif., June 21, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that Dr. Jeffrey S. Miller will be giving an update on the progress of the GTB-3550 TriKE™ Phase I trial accompanying the Company's corporate update presentation at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.
A live webcast of the event will be available by visiting the "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations. A replay of the webcast will be archived for 30 days following the presentation.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology. For more information, please visit gtbiopharma.com.
Investor Contact:
Brendan Payne
Client Lead
Stern Investor Relations, Inc.
brendan.payne@sternir.com
212-362-1200
Investor and Media Relations Contact
David Castaneda
David@gtbiopharma.com
414-351-9758
View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-jeffrey-s-miller-to-present-on-progress-of-gtb-3550-trike-phase-i-trial-accompanying-gt-biopharmas-company-presentation-at-raymond-james-human-health-innovation-conference-301316040.html
SOURCE GT Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.